Frail older people with diabetes are unlikely to benefit from treatment intensification and are more likely to experience its side effects. These include hypoglycaemia, falls, adverse drug effects, weight loss that can worsen frailty, and complications related to comorbidities and shortened life expectancy.

The text states that frail people with significant comorbidities or cognitive/functional impairment are unlikely to reap the benefits of intensifying diabetes treatments and are more likely to suffer the side effects of over-intensification. Managing diabetes in this group is further complicated by comorbidities, shortened life expectancy, potential adverse treatment effects, risk of falls from muscle loss and reduced strength, and nutritional challenges. Specific glucose-lowering therapy risks include hypoglycaemia with sulfonylureas and insulin, renal impairment requiring dose adjustments, volume depletion with SGLT2 inhibitors, contraindications of saxagliptin and pioglitazone in heart failure, weight loss that can precipitate or worsen frailty, and fracture risk with pioglitazone in people with low bone density. The guidance therefore emphasizes avoiding unnecessary intensification, simplifying regimens, and reviewing medications carefully, especially after acute illness or hospital admission.

Key points

Frail older adults are unlikely to gain benefit from treatment intensification and are more prone to side effects.
Over-intensification risks include hypoglycaemia, falls, adverse drug effects, and worsening frailty through weight loss.
Sulfonylureas and insulin carry particular hypoglycaemia risk in frail people with type 2 diabetes.
Other medication risks include renal impairment, volume depletion, heart failure contraindications, and fracture risk.
Management should account for comorbidities, shortened life expectancy, and nutritional challenges.

What are the risks of over-intensification of therapies in frail older people with diabetes?

Related questions